INCARA PHARMACEUTICALS CORP Form SC 13G/A February 10, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

Incara Pharmaceuticals Corporation

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45325 S-10-1

(CUSIP Numbers)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
"Rule 13d-1(b)
"Rule 13d-1(c)
x Rule 13d-1(d)
* The consider of this cover mass shall be filled out for a generating nearon a initial filing on this form with respect to the subject class of

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

1.	Name of Reporting Person					
	I.R.S. Identification No. of above person (Entities Only)					
	Clay	ton I. Duncan				
2. Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a) "					
	(b) "					
	Not Applica	ble				
3.	SEC Use Only					
4.	. Citizenship or Place of Organization					
United States						
		5. Sole Voting Power				
NU	UMBER OF	1,931,170				
SHARES		6. Shared Voting Power				
BENEFICIALLY						
0	WNED BY	0				
	EACH	7. Sole Dispositive Power				
RI	EPORTING					
	PERSON	1,931,170				
	WITH	8. Shared Dispositive Power				
		0				

9. Aggregate Amount Beneficially Owned by Each Reporting Person

	1,931,170				
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
	Not Applicable				
11.	Percent of Class Represented by Amount in Row (9)				
	4.0%				
12.	Type of Reporting Person (See Instructions)				
	IN				

Item 1(a) Name of Issuer:

Incara Pharmaceuticals Corporation

Item 1(b) Address of Issuer s Principal Executive Offices

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287, Research Triangle Park, NC 27709-4287

Item 2(a) Name of Person Filing:

Clayton I. Duncan

Item 2(b) Address of Principal Business Office or, if none, Residence:

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287, Research Triangle Park, NC 27709-4287

Item 2(c) Citizenship:

United States

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

45325 S-10-1

Item 3. Filing Pursuant to Rules 13d-1(b) or 13d-2(b)

Not Applicable

Item 4. Ownership

(a) As of December 31, 2003, Mr. Duncan beneficially owned an aggregate of 1,931,170 shares of the Issuer s Common Stock which includes (i) 452,470 shares owned by Mr. Duncan, (ii) 192,000 shares owned by Mr. Duncan s children, (iii) 102,700 shares owned by a family LLC, (iv) 1,169,120 shares issuable upon exercise of options held by Mr. Duncan and (v) 14,880 shares issuable upon exercise of warrants held by the family LLC. Mr. Duncan disclaims beneficial ownership of the shares held by his children.

- (b) Percent of class: 4.0%. This final Schedule 13G is being filed because the ownership has decreased to less than 5% due to the issuance of additional shares of common stock by Incara Pharmaceuticals Corporation.
- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote: <u>1,931,170</u>
 - (ii) Shared power to vote or to direct the vote: $\underline{0}$
 - (iii) Sole power to dispose or to direct the disposition of: 1,931,170
 - (iv) Shared power to dispose or to direct the disposition of: $\underline{0}$
- Item 5. Ownership of Five Percent or Less of a Class

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

Not Applicable

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 6, 2004							
Dat	e						
/s/	Clayton I. Duncan						

Clayton I. Duncan